Treatment With Cladribine Selects IFNγ+IL17+ T Cells in RRMS Patients – An In Vitro Study

Treatment With Cladribine Selects IFNγ+IL17+ T Cells in RRMS Patients – An In Vitro Study

BackgroundMultiple sclerosis (MS) is an incurable autoimmune disease mediated by a heterogeneous T cell population (CD3+CD161+CXCR3−CCR6+IFNγ−IL17+, CD3+CXCR3+CCR6+IFNγ+IL17+, and CD3+CXCR3+IFNγ+IL17− phenotypes) that infiltrates the central nervous system, eliciting local inflammation, demyelinatio...

Full description

Bibliographic Details
Main Authors: Minodora Dobreanu, Doina Ramona Manu, Ion Bogdan Mănescu, Manuela Rozalia Gabor, Adina Huţanu, Laura Bărcuţean, Rodica Bălaşa
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-12-01
Series:Frontiers in Immunology
Subjects:
relapsing-remitting multiple sclerosis (RRMS)
cladribine
T cells
IFNγ+IL17+ cells
Th17.1 cells
in vitro
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.743010/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.743010/full

Similar Items